SCHEMBL9811069

SCHEMBL9811069

Fc1cccc2c1C(F)c1ccccc1-2

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPIA P62937 6/20 0.43
HTR2A P28223 1/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNA4 P43681 1/20 0.38
TNKS2 Q9H2K2 1/20 0.36
KDM1A O60341 2/20 0.35
KDM1B Q8NB78 1/20 0.35
SMARCA2 P51531 1/20 0.35
SMARCA4 P51532 1/20 0.35
PBRM1 Q86U86 1/20 0.35
GPR3 P46089 1/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
CYP19A1 P11511 1/20 0.33
PDK2 Q15119 1/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL7516104 0.78 CHRNB2 (0.42) PPIACHRNB2CHRNA4KDM1AKDM1B
SCHEMBL28865931 0.78 PPIA (0.46) PPIACHRNB2CHRNA4TNKS2PDK2
SCHEMBL18242520 0.78 PPIA (0.49) PPIACHRNB2CHRNA4TNKS2KDM1A
SCHEMBL29797969 0.77 GPR3 (0.46) HTR2AGPR3CYP19A1
SCHEMBL4359049 0.77 GPR3 (0.46) HTR2AGPR3CYP19A1
Hydrochloric Acid SCHEMBL7606641 0.76 CHRNB2 (0.41) PPIACHRNB2CHRNA4KDM1AKDM1B
SCHEMBL4011644 0.75 HTR7 (0.30) HTR2AGPR3
SCHEMBL28773457 0.75 IDO1 (0.41) PPIAHTR2ACHRNB2CHRNA4KDM1A
SCHEMBL28619081 0.73 CA1 (0.40) PPIATNKS2SMARCA2SMARCA4PBRM1
SCHEMBL7111303 0.73 MEN1 (0.39) PPIAHTR2AGPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250120252-A1 MATERIALS FOR FORMING A NUCLEATION-INHIBITING COATING AND DEVICES INCORPORATING SAME OTI LUMIONICS INC. (CA) 2025-04-10 US claimed
US-12178064-B2 Materials for forming a nucleation-inhibiting coating and devices incorporating same OTI LUMIONICS INC. (CA) 2024-12-24 US claimed
US-12069939-B2 Method for patterning a coating on a surface and device including a patterned coating OTI LUMIONICS INC. (CA) 2024-08-20 US claimed
US-20230363196-A1 MATERIALS FOR FORMING A NUCLEATION-INHIBITING COATING AND DEVICES INCORPORATING SAME OTI LUMIONICS INC. (CA) 2023-11-09 US claimed
CN-116583131-A Method for patterning a surface coating and apparatus comprising a patterned coating OTI照明公司 2023-08-11 CN claimed
US-20230165124-A1 METHOD FOR PATTERNING A COATING ON A SURFACE AND DEVICE INCLUDING A PATTERNED COATING OTI LUMIONICS INC. (CA) 2023-05-25 US claimed
US-11581487-B2 Patterned conductive coating for surface of an opto-electronic device OTI LUMIONICS INC. (CA) 2023-02-14 US claimed
US-12590244-B2 Method for patterning a coating on a surface and device including a patterned coating OTI LUMIONICS INC. (CA) 2026-03-31 US disclosed
US-20250120252-A1 MATERIALS FOR FORMING A NUCLEATION-INHIBITING COATING AND DEVICES INCORPORATING SAME OTI LUMIONICS INC. (CA) 2025-04-10 US disclosed
US-20250024700-A1 DEVICE INCLUDING A CONDUCTIVE COATING DISPOSED OVER EMISSIVE REGIONS AND METHOD THEREFOR OTI Lumonics Inc. (CA) 2025-01-16 US disclosed
US-12178064-B2 Materials for forming a nucleation-inhibiting coating and devices incorporating same OTI LUMIONICS INC. (CA) 2024-12-24 US disclosed
US-12150374-B2 Method for patterning a coating on a surface and device including a patterned coating OTI LUMIONICS INC. (CA) 2024-11-19 US disclosed
US-20240381754-A1 METHOD FOR PATTERNING A COATING ON A SURFACE AND DEVICE INCLUDING A PATTERNED COATING OTI LUMIONICS INC. (CA) 2024-11-14 US disclosed
US-4540700-A Treatment of diabetic complications with certain spiro-imidazolidine-diones ALCON LABORATORIES, INC. (US) 1985-09-10 US disclosed
US-4438272-A COMPLICATIONS OF DIABETES ALCON LABORATORIES, INC. (US) 1984-03-20 US disclosed
US-4436745-A TETRACYCLIC SPIROHYDANTOINS ALCON LABORATORIES, INC. (US) 1984-03-13 US disclosed
WO-1983003543-A1 METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS ALCON LAB INC (US) 1983-10-27 WO disclosed
WO-1983003543-A1 METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS ALCON LAB INC (US) 1983-10-27 WO disclosed
EP-0092385-A2 Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds ALCON LABORATORIES, INC. (US) 1983-10-26 EP disclosed
EP-0092385-A2 Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds ALCON LABORATORIES, INC. (US) 1983-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590244-B2 Method for patterning a coating on a surface and device including a patterned coating FLNB, FZD7, ITGB6 PPIA 1740/4885HTR2A 2156/4885CHRNB2 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.